ClinicalTrials.gg
RecruitingNCT07831343HOSPIC-6Updated Nov 2, 2026

Hospital-Based Prospective Cohort of Malnutrition Under 6-Month Study (HOSPIC-6-Study)

An observational study in Malnutrition, Infant and Malnutrition, sponsored by Universitas Indonesia. Recruiting at 16 sites in Indonesia. Open to participants aged 1 Day to 6 Months. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Universitas Indonesia · Observational

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 2, 2026Primary outcomes revised12 sites addedGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,780
Ages
1 Day to 6 Months
Sex
All
01

Study summary

This study is a hospital-based, prospective, multicentre cohort study (the HOSPIC-6 Study) that will follow infants under 6 months of age who are admitted to pediatric or perinatology wards with acute malnutrition, diagnosed according to the 2023 WHO criteria. The study will take place at Cipto Mangunkusumo Hospital (RSCM) in Jakarta, Indonesia, together with other hospitals all over Indonesia joining the HOSPIC-6 network, over a period of about one year.

The purpose of this study is to:

  1. Describe how common acute malnutrition is among infants under 6 months admitted to these hospitals
  2. Observe what happens to these infants during nutrition treatment: whether they recover, whether their growth improves, or whether they experience complications or death.
  3. Look at the factors associated with succesful nutrition therapy outcomes.

After enrolment, each infant's weight, length, head circumference, and mid-upper arm circumference will be measured using standardized techniques, along with information about their birth history, feeding history, and any other illnesses. These measurements, along with details of the nutrition therapy provided, will be repeated on day 3, day 7, and then weekly until the infant is discharged from the hospital. All data will be recorded in a secure, password-protected electronic database (REDCap). No experimental drug or intervention will be given as part of this study; infants will receive the nutrition care that their treating doctors already provide as standard practice, and the study will only observe and record what happens.

The information gathered from this study is expected to help doctors and health authorities better understand the scale of this problem in Indonesia and to support the development of clearer, evidence-based feeding and calorie guidelines for the treatment of acute malnutrition in infants under 6 months of age.

Read the detailed description

Rationale and Scientific Background Acute malnutrition in infants younger than 6 months has historically received less attention than malnutrition in older children, both in global nutrition programs and in national health monitoring systems. The World Health Organization (WHO) 2013 guideline on the management of severe acute malnutrition addressed infants under 6 months only briefly, largely extrapolating recommendations developed for older children. The WHO 2023 guideline expanded this guidance substantially, introducing the broader concept of infants "at risk of poor growth and development" alongside the traditional anthropometric thresholds (weight-for-age, weight-for-length, and mid-upper arm circumference).

National data support the clinical relevance of this population. The 2023 Indonesian Health Survey / Survey Kesehatan Indonesia (SKI) reported a 2.6% prevalence of acute malnutrition among infants aged 0-5 months, and the 2024 Indonesian Nutritional Status Survey / Survei Status Gizi Indonesia (SSGI) reported 1.6% in the same age group - both higher than prevalence figures reported for children 24 months and older. Institutional data from Cipto Mangunkusumo Hospital / Rumah Sakit Ciptomangunkusumo (RSCM) identified 282 infants under 6 months admitted with severe malnutrition in 2024 alone.

Despite this burden, the current WHO 2023 guideline does not specify detailed, concrete caloric targets for nutritional therapy in this age group, and there are no Indonesian studies linking specific nutrition therapy approaches, patient risk factors, and treatment outcomes in this population. This creates uncertainty in day-to-day clinical decision-making and a gap in the evidence needed to develop a standardized, locally relevant treatment protocol. This study (HOSPIC-6) was designed to generate multicenter, prospective, hospital-based evidence to help close this gap.

Research Questions and Objectives

This study is designed to address three research questions:

  1. What is the prevalence of acute malnutrition among infants under 6 months admitted to participating hospitals?
  2. What proportion of infants experience each type of nutrition therapy outcome (successful therapy, death, or improvement in nutritional status)?
  3. What factors are associated with successful nutrition therapy in this population?

The general objective is to characterize the clinical management challenges of acute malnutrition in infants under 6 months. The specific objectives are to determine:

  1. The prevalence of acute malnutrition in this age group,
  2. The proportion of nutrition therapy outcomes among affected infants, and
  3. The factors associated with successful nutrition therapy outcomes.

Hypothesis The investigators hypothesize that the outcome of nutrition therapy in infants under 6 months with acute malnutrition - including growth improvement, treatment success, and survival - is influenced by measurable and identifiable clinical factors (such as gestational history, comorbidities, type of nutritional support received, and achieved daily caloric intake), and that characterizing these factors will help inform more effective, evidence-based treatment strategies.

Study Procedures and Data Collection All infants under 6 months admitted to participating pediatric or perinatology wards will first undergo baseline screening data collection (age, sex, gestational age, weight, length, and mid-upper arm circumference if organomegaly is present). Infants who meet WHO 2023 acute malnutrition criteria and do not meet any exclusion criteria will be enrolled as study subjects after informed consent is obtained; infants who are screened but not enrolled will still have their baseline screening data entered into the study's REDCap database for descriptive purposes.

For enrolled subjects, baseline data collected include anthropometric measurements (weight, length, mid-upper arm circumference, and head circumference obtained using standardized equipment and techniques according to Indonesian Ministry of Health regulation No. HK.01.07/MENKES/51/2022), demographic information, comorbidities, birth history, and nutritional history. Details of the nutrition therapy provided (e.g., breast milk, therapeutic milk such as F-75 or diluted F-100, or infant formula) and available laboratory results are also recorded. Follow-up data collection, including repeat anthropometric measurements, ongoing nutrition therapy details, and available laboratory results, occurs on Day 3, Day 7, and then weekly until the infant is discharged. At each time point, the percentage of estimated daily caloric needs achieved is also recorded.

Registry Infrastructure and Data Management All study data are captured directly into REDCap (Research Electronic Data Capture), a secure, access-controlled electronic data capture platform, using a structured electronic case report form built specifically for this protocol. Use of a single shared REDCap database across all participating sites is intended to standardize data structure and definitions across the multicentre network, rather than relying on site-specific paper records that would later require harmonization.

Data Validation and Quality Assurance The REDCap case report form incorporates field-level validation rules (for example, restricting anthropometric values to clinically plausible ranges and enforcing required fields for key variables such as enrollment eligibility criteria) to reduce data entry error at the point of capture. The principal investigator's team performs centralized data verification and cleaning of records entered into REDCap on an ongoing basis, cross-checking entries for internal consistency (for example, agreement between recorded eligibility criteria and enrollment status) and following up directly with local investigators when discrepancies, implausible values, or missing critical fields are identified.

Roles and Responsibilities The principal investigator team is responsible for developing and maintaining the study protocol, the REDCap database structure, and the ethics/regulatory documentation, as well as for centralized data verification and cleaning. Local investigators at each participating site are responsible for obtaining local research permits, ensuring anthropometric equipment at their site is available, calibrated, and used according to the standard operating procedure specified in the protocol, ensuring eligible subjects are identified and enrolled consecutively according to protocol, obtaining informed consent, and entering (or supervising the entry of) subject data into REDCap in a timely manner. This division of responsibilities functions as the study's core standard operating procedure for recruitment, data collection, and data management across sites; coordination between the principal investigator team and local investigators occurs as needed throughout enrollment and follow-up to resolve site-level questions or data queries.

Source Data Verification. Data entered into REDCap are expected to be traceable to source documentation at each site (hospital medical records and/or paper case report forms completed at the bedside at the time of measurement), allowing source data verification and consistency checks against the electronic record as part of routine data cleaning.

Data Dictionary A structured data dictionary underlies the REDCap database, defining each variable collected (for example, anthropometric measures, nutrition therapy type, and outcome classification), its permitted values or coding scheme, and its collection time point, to ensure consistent interpretation and entry of each field across all participating sites.

Handling of Missing Data Because this is an observational, hospital-based cohort in which not every laboratory test or measurement is routinely available for every infant at every time point (for example, laboratory results are recorded only when clinically obtained as part of standard care), some degree of missing data is anticipated, particularly for laboratory variables, rather than for core anthropometric measurements, which are collected prospectively as part of the study procedure at each scheduled time point. Data queries generated during centralized cleaning (for missing, out-of-range, or internally inconsistent entries) are routed back to the responsible local investigator for resolution against source documentation where possible. Where a data point remains genuinely unavailable (for example, a laboratory test not clinically indicated or not performed), it is recorded as missing rather than imputed at the point of data entry. The approach to handling such missingness in the final analytic dataset (for example, complete-case analysis for the specific variable, or descriptive reporting of missingness) will be determined at the analysis stage according to the extent and pattern of missingness observed for each variable, following standard descriptive and analytic conventions for observational cohort data.

Statistical Analysis Plan Descriptive statistics will be used to characterize the screened and enrolled populations and to estimate the prevalence of acute malnutrition among infants under 6 months admitted to participating hospitals with corresponding proportions reported for each nutrition therapy outcome category (treatment success, death, and improvement in nutritional status). Continuous variables such as, anthropometric measures and estimated caloric intake will be summarized as means with standard deviations or medians with interquartile ranges, depending on their distribution, and categorical variables will be summarized as frequencies and percentages. Bivariate comparisons between infants with successful versus unsuccessful nutrition therapy outcomes will be conducted using chi-square or Fisher's exact tests for categorical variables and t-tests or non-parametric equivalents for continuous variables, as appropriate to the data distribution. Factors independently associated with successful nutrition therapy outcomes will be assessed using multivariable regression analysis (logistic regression), adjusting for clinically relevant covariates such as gestational history, comorbidities, and achieved caloric intake. A two-sided p-value of less than 0.05 will generally be considered statistically significant, and results will be reported with corresponding effect estimates and 95% confidence intervals.

Significance As a purely observational, hospital-based registry-style cohort with no experimental intervention, HOSPIC-6 is designed to generate real-world, multicenter evidence on the epidemiology and treatment outcomes of acute malnutrition in infants under 6 months in Indonesia. Its centralized REDCap infrastructure, standardized measurement procedures, and structured data verification process are intended to support data quality across a multicenter, resource-varied hospital network. Findings are expected to inform the development of a more detailed, locally relevant clinical pathway - including specific caloric targets - for the management of acute malnutrition in this age group, both at network hospital and more broadly within the Indonesian health system.

02

Conditions studied

  • Malnutrition, Infant
  • Malnutrition

Keywords

  • Malnutrition
  • Infant
  • Acute Malnutrition
  • Wasting
  • Nutritional Oedema
  • Nutritional Therapy
  • Anthropometry
  • Mid-Upper Arm Circumference
  • Treatment Outcome
  • Prospective Cohort Studies
  • Infant Under 6 months
03

In context

Infant Nutrition Disorders

67 studies on the registry are indexed under Infant Nutrition Disorders; 14 are open to participants now.

This study's planned enrollment of 1,780 is above the median of 203 across 20 observational studies indexed under Infant Nutrition Disorders.

Browse Infant Nutrition Disorders studies →

Lead sponsor

Universitas Indonesia is the lead sponsor of 35 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Infants under 6 months of age admitted to inpatient care in pediatric and perinatology wards at RSCM and partner hospitals/centers that join the HOSPIC-6 collaborative network.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants under 6 months of age admitted to inpatient care who meet the WHO 2023 criteria for acute malnutrition.
  • For infants aged 0-1 month, criteria include a documented weekly weight gain of less than 200 grams, or failure to return to birth weight by 2 weeks of chronological age.
  • For infants aged 1 month to under 6 months, at least one of the following is required:

    • Weight-for-age less than -2 SD
    • Weight-for-length less than -2 SD, or
    • Mid-upper arm circumference under 110 mm (for infants older than 6 weeks), with or without nutritional oedema, and currently receiving treatment for acute malnutrition.
  • Parents or legal guardians must provide written .

Exclusion criteria

Exclusion criteria:

  • Infants with inborn error of metabolism
  • Infant with syndromic condition (e.g., Down syndrome, Silver-Russell syndrome, Turner syndrome, Klinefelter syndrome, or other diagnosed syndromic conditions),
  • Infant with anatomical abnormality affecting body weight, such as hydrocephalus.

Drop Outs Criteria:

Participants will be considered "drop-outs" if they are discharged against medical advice or transferred to a non-participating hospital.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,780 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Infants Under 6 Months of Age with Acute Malnutrition based on WHO 2023 Guideline

    Infants under 6 months of age fulfilling acute malnutrition criteria based on WHO 2023

    Other: Not applicable- observational study

Interventions

  • OtherNot applicable- observational study

    No intervention (observational study)

06

What researchers measure

Primary outcomes

  1. Change in nutritional status

    Change in nutritional status as indicated by change in z-score toward the age- and sex-specific reference, as determined using the PediTools online calculator. The 24-week upper bound is to accommodate prolonged hospitalization in infants with severe comorbidities requiring extended nutritional stabilization.

    Time frame: Baseline, Day 3, Day 7, and weekly thereafter through hospital discharge, up to 24 weeks, whichever comes first.

Secondary outcomes

  1. All-cause mortality

    Proportion of infants under 6 months with acute malnutrition who died from any cause during hospitalization.

    Time frame: From baseline until death or hospital discharge, up to 24 weeks.

Other outcomes

  1. Average Daily Caloric Intake

    Mean daily caloric intake achieved (kcal/kgBW/day), recorded from nutritional therapy documentation at each assessment point.

    Time frame: Baseline, Day 3, Day 7, and weekly thereafter through hospital discharge, up to 24 weeks, whichever comes first.

07

Study locations

16 of 16 sites recruiting
  • RSUP Prof. Dr. I.G.N.G. Ngoerah
    Denpasar, Bali 80113, Indonesia
    Recruiting
    • Dr. dr. I Gusti Lanang Sidhiarta, SpA(K) · Contactlanangsidiartha@yahoo.com · +62 822 3682 1069
    • I Gusti L Sidiarta, MD,PhD,SpA(K) · Principal investigator
  • RSUP Dr. Kariadi Semarang
    Semarang, Central Java 50244, Indonesia
    Recruiting
    • dr. Rina Pratiwi, MSi.Med, SpA(K) · Contactrinapratiwi18@gmail.com · +62 8122824170
    • Rina Pratiwi, MD, SpA(K) · Principal investigator
  • RS Universitas Sebelas Maret
    Sukoharjo, Central Java 57161, Indonesia
    Recruiting
    • dr. Maria Galuh Kamenyangan Sari, SpA(K), M.Kes. · Contactmaria.galuh@yahoo.com · +62 81225700283
    • Maria GK Sari, MD,SpA(K) · Principal investigator
  • RSUP Dr. Sardjito
    Yogyakarta, DI Yogyakarta 55284, Indonesia
    Recruiting
    • Dr. dr. Neti Nurani, M.Kes, Sp.A (K) · Contactneti.nurani@ugm.ac.id · +62 821 17231524
    • Neti Nurani, MD,PhD,SpA(K) · Principal investigator
  • Cipto Mangunkusumo Hospital
    Jakarta Pusat, DKI Jakarta 10320, Indonesia
    Recruiting
    • dr. Yoga Devaera, SpA(K), PhD · Contactyoga.devaera@ui.ac.id · (+62) 8129431861
    • dr. Vembricha N Manusita, SpA · Contactvembricha.nindya@gmail.com · (+62) 82333 458700
    • Yoga Devaera, MDPhD SpA(K) · Principal investigator
    • Vembricha N Manusita, MD, SpA · Sub investigator
    • Immaculata Purwaningsih, MD, SpA · Sub investigator
  • RSIA Bunda Jakarta
    Jakarta Pusat, DKI Jakarta 10350, Indonesia
    Recruiting
    • dr. Dimple Nagrani, SpA · Contactdimple.nagrani@gmail.com · (+62) 817811131
    • Dimple Nagrani, MD, SpA · Principal investigator
  • RSAB Harapan Kita
    Jakarta Pusat, DKI Jakarta 11420, Indonesia
    Recruiting
    • dr. Novitria Dwinanda, SpA(K) · Contactnovitria.dwinanda@gmail.com · +62 81210493502
    • dr. Prajnya Paramitha Narendraswari · Contactprajnyaparamitha@gmail.com · +62 812 1215 6238
    • Novitria Dwinanda, MD,SpA(K) · Principal investigator
    • Prajnya P Narendraswari, MD, SpA · Sub investigator
  • RSUD Prof. Dr. W. Z. Johannes Kupang
    Kupang, East Nusa Tenggara 85111, Indonesia
    Recruiting
    • Dr. dr. Irene K. L. A. Davidz, SpA., M.Kes · Contactirenekathreendavidz@gmail.com · +62 813 4226 9275
    • Irene KLA Davidz, MD,PhD,SpA · Principal investigator
  • RSUD H. Abdul Manap Kota Jambi
    Jambi City, Jambi, Indonesia
    Recruiting
    • dr. Vivi Septriani, SpA · Contactviviseptriani@gmail.com · (+62) 8994478233
    • Vivi Septriani, MD, SpA · Principal investigator
  • RSUD Abdul Moeleok
    Bandar Lampung, Lampung 35112, Indonesia
    Recruiting
    • dr. Arief Rahman, SpA · Contactariefdoctor88@gmail.com · +62 812 7332 1578
    • Arief Rahman, MD, SpA · Principal investigator
  • RSUP Prof. Dr. R. D. Kandou
    Manado, North Sulawesi 95163, Indonesia
    Recruiting
    • dr. Bobby Pambudi, SpA(K) · Contactbobby_pam2003@hotmail.com · +62 853-4020-7704
    • Bobby Pambudi, MD, SpA(K) · Principal investigator
  • RSUD Arifin Achmad Pekanbaru
    Pekanbaru, Riau 28156, Indonesia
    Recruiting
    • dr. Mislina Munir, M.Ked(Ped), SpA(K) · Contactilinmislinamunir@gmail.com · +6281371720071
    • Mislina Munir, MD,SpA(K) · Principal investigator
  • RSUP Dr. Mohammad Hoesin Palembang
    Palembang, South Sumatra 30126, Indonesia
    Recruiting
    • dr. Moretta Damayanti, SpA(K) · Contactmd4eay@gmail.com · +62 813 8774 3885
    • Moretta Damayanti, MD,SpA(K) · Principal investigator
  • RSUP Dr. Hasan Sadikin
    Bandung, West Java 40161, Indonesia
    Recruiting
    • dr. Viramitha Kusnandi Rusmil, SpA(K) · Contactvirmith@yahoo.com · +62 821 2915 9149
    • Viramitha K Rusmil, MD,SpA(K) · Principal investigator
  • RSUP Sidawangi
    Cirebon, West Java, Indonesia
    Recruiting
  • RSUD Cideres
    Majalengka, West Java 45453, Indonesia
    Recruiting
    • dr. Mohamad Y Anggara, SpA · Contactyanuaranggara@yahoo.co.id · (+62) 82128119691
    • Mohamad Y Anggara, MD, SpA · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data collected in this study (HOSPIC-6 Study) may be made available to other researchers upon reasonable request to the principal investigator.

Supporting information: Clinical study report

Time frame: Data will be made available beginning after publication of the primary study results, for a period to be determined by the principal investigator and for as long as the principal investigator's team is able to support such requests.

Access criteria: Requests should be directed to the principal investigator of the HOSPIC-6 Study. Access will be granted to qualified researchers who submit a methodologically sound request for a specified analytic purpose, subject to review and approval by the principal investigator and, where required, execution of a data use/sharing agreement and any additional institutional or ethics committee approvals necessary at the requestor's institution.

No publications or documents are linked to this record.

09

Updates

7 registry updates since Sep 25, 2026
Sites
12 sites added
Show 12 added (12 Indonesia)
  • RSUP Dr. Kariadi Semarang · Semarang, Indonesia
  • RSIA Bunda Jakarta · Jakarta Pusat, Indonesia
  • RSAB Harapan Kita · Jakarta Pusat, Indonesia
  • RSUP Prof. Dr. R. D. Kandou · Manado, Indonesia
  • RSUP Dr. Hasan Sadikin · Bandung, Indonesia
  • RSUP Dr. Sardjito · Yogyakarta, Indonesia
  • RSUP Prof. Dr. I.G.N.G. Ngoerah · Denpasar, Indonesia
  • RS Universitas Sebelas Maret · Sukoharjo, Indonesia
  • RSUD Prof. Dr. W. Z. Johannes Kupang · Kupang, Indonesia
  • RSUD Arifin Achmad Pekanbaru · Pekanbaru, Indonesia
  • RSUP Dr. Mohammad Hoesin Palembang · Palembang, Indonesia
  • RSUD Abdul Moeleok · Bandar Lampung, Indonesia
across 6 updates, Oct 7, 2026 – Nov 2, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedImprovementChange in nutritional statusTime frame: Baseline, Day 3, Day 7, and weekly thereafter through hospital discharge, up to 24 weeks, whichever comes first.
Sep 29, 2026
Show all 7 updates
  1. Nov 2, 2026
    1 site added
    Show site
    • RSUD Abdul Moeleok · Bandar Lampung, Indonesia
  2. Oct 29, 2026
    5 sites added
    Show 5 added (5 Indonesia)
    • RSUP Prof. Dr. I.G.N.G. Ngoerah · Denpasar, Indonesia
    • RS Universitas Sebelas Maret · Sukoharjo, Indonesia
    • RSUD Prof. Dr. W. Z. Johannes Kupang · Kupang, Indonesia
    • RSUD Arifin Achmad Pekanbaru · Pekanbaru, Indonesia
    • RSUP Dr. Mohammad Hoesin Palembang · Palembang, Indonesia
  3. Oct 20, 2026
    1 site added
    Show site
    • RSUP Dr. Sardjito · Yogyakarta, Indonesia
  4. Oct 16, 2026
    3 sites added
    Show 3 added (3 Indonesia)
    • RSAB Harapan Kita · Jakarta Pusat, Indonesia
    • RSUP Prof. Dr. R. D. Kandou · Manado, Indonesia
    • RSUP Dr. Hasan Sadikin · Bandung, Indonesia
  5. Oct 9, 2026
    1 site added
    Show site
    • RSIA Bunda Jakarta · Jakarta Pusat, Indonesia
  6. Oct 7, 2026
    1 site added
    Show site
    • RSUP Dr. Kariadi Semarang · Semarang, Indonesia
    + 1 other change: verification date
  7. Sep 29, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedImprovementChange in nutritional statusTime frame: Baseline, Day 3, Day 7, and weekly thereafter through hospital discharge, up to 24 weeks, whichever comes first.

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07831343
Lead sponsor
Universitas Indonesia
Responsible party
dr. Yoga Devaera (Medical Doctor, Pediatrician, PhD, Universitas Indonesia) — Principal investigator
First posted
Sep 21, 2026
Start date
Aug 28, 2026
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

dr. Yoga Devaera, SpA(K), PhD
Contact
yoga.devaera@ui.ac.id
(+62) 8129431861
dr. Vembricha N Manusita, SpA
Contact
vembricha.nindya@gmail.com
(+62) 82333 458700
Yoga Devaera, MDPhD SpA(K)
principal investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion